Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism

Journal of Immunology

Volumn 187, Issue 12, 2011, Pages 6310-6317

  LaCasse, Collin J ^a,b   Janikashvili, Nona ^a   Larmonier, Claire B ^a   Alizadeh, Darya ^a,c   Hanke, Neale ^a,c   Kartchner, Jessica ^a   Situ, Elaine ^a   Centuori, Sara ^a,c   Har Noy, Michael ^d   Bonnotte, Bernard ^e   Katsanis, Emmanuel ^a,b,c,f   Larmonier, Nicolas ^a,b,c,f  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UNIVERSITÉ DE BOURGOGNE   (France)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; BONE MARROW CELLS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, INTERFERON; TH1 CELLS;

EID: 83755173186     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101812     Document Type: Article

References (49)

1. Palucka, K., H. Ueno, G. Zurawski, J. Fay, and J. Banchereau. 2010. Building on dendritic cell subsets to improve cancer vaccines. Curr. Opin. Immunol. 22: 258-263.
2. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15: 138-147. (Pubitemid 36287518)
3. Banchereau, J., E. Klechevsky, N. Schmitt, R. Morita, K. Palucka, and H. Ueno. 2009. Harnessing human dendritic cell subsets to design novel vaccines. Ann. N. Y. Acad. Sci. 1174: 24-32.
4. Nicolas, A., D. Cathelin, N. Larmonier, J. Fraszczak, P. E. Puig, A. Bouchot, A. Bateman, E. Solary, and B. Bonnotte. 2007. Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. J. Immunol. 179: 812-818.
5. Fraszczak, J., M. Trad, N. Janikashvili, D. Cathelin, D. Lakomy, V. Granci, A. Morizot, S. Audia, O. Micheau, L. Lagrost, et al. 2010. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. J. Immunol. 184: 1876-1884.
6. Shi, J., K. Ikeda, N. Fujii, E. Kondo, K. Shinagawa, F. Ishimaru, K. Kaneda, M. Tanimoto, X. Li, and Q. Pu. 2005. Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci. 96: 127-133. (Pubitemid 40425389)
7. Josien, R., M. Heslan, J. P. Soulillou, and M. C. Cuturi. 1997. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J. Exp. Med. 186: 467-472. (Pubitemid 27332906)
8. Stary, G., C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl. 2007. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204: 1441-1451. (Pubitemid 46919881)
9. Huang, J., T. Tatsumi, E. Pizzoferrato, N. Vujanovic, and W. J. Storkus. 2005. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res. 65: 8461-8470. (Pubitemid 41330614)
10. Süss, G., and K. Shortman. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183: 1789-1796.
11. Lu, L., S. Qian, P. A. Hershberger, W. A. Rudert, D. H. Lynch, and A. W. Thomson. 1997. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 158: 5676-5684. (Pubitemid 127483971)
12. Legge, K. L., and T. J. Braciale. 2005. Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity 23: 649-659. (Pubitemid 41779486)
13. Shibaki, A., and S. I. Katz. 2001. Activation through CD40 ligation induces functional Fas ligand expression by Langerhans cells. Eur. J. Immunol. 31: 3006-3015. (Pubitemid 32994552)
14. Manna, P. P., and T. Mohanakumar. 2002. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J. Leukoc. Biol. 72: 312-320.
15. Ayres, F. M., M. Narita, M. Takahashi, T. Yano, A. Liu, K. Toba, T. Furukawa, and Y. Aizawa. 2004. Human dendritic cells mediate anti-tumor activity against hematopoietic tumor cells without direct contact and Fas/FasL killing pathway. Oncol. Rep. 11: 1017-1023.
16. Lu, G., B. M. Janjic, J. Janjic, T. L. Whiteside, W. J. Storkus, and N. L. Vujanovic. 2002. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. 168: 1831-1839. (Pubitemid 34135783)
17. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189: 1343-1354.
18. Vidalain, P. O., O. Azocar, H. Yagita, C. Rabourdin-Combe, and C. Servet-Delprat. 2001. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J. Immunol. 167: 3765-3772. (Pubitemid 32910822)
19. Liu, S., Y. Yu, M. Zhang, W. Wang, and X. Cao. 2001. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J. Immunol. 166: 5407-5415. (Pubitemid 32374160)
20. Chaperot, L., A. Blum, O. Manches, G. Lui, J. Angel, J. P. Molens, and J. Plumas. 2006. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 176: 248-255. (Pubitemid 43023269)
21. Janjic, B. M., G. Lu, A. Pimenov, T. L. Whiteside, W. J. Storkus, and N. L. Vujanovic. 2002. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J. Immunol. 168: 1823-1830. (Pubitemid 34135782)
22. Alli, R., B. Savithri, S. Das, C. Varalakshmi, N. Rangaraj, and A. Khar. 2004. Involvement of NKR-P2/NKG2D in DC-mediated killing of tumor targets: indicative of a common, innate, target-recognition paradigm? Eur. J. Immunol. 34: 1119-1126. (Pubitemid 39255991)
23. Srivastava, R. M., Ch. Varalakshmi, and A. Khar. 2007. Cross-linking a mAb to NKR-P2/NKG2D on dendritic cells induces their activation and maturation leading to enhanced anti-tumor immune response. Int. Immunol. 19: 591-607. (Pubitemid 47072203)
24. Tatsumi, T., J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus. 2003. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 63: 6378-6386. (Pubitemid 37255187)
25. Hardy, A. W., D. R. Graham, G. M. Shearer, and J. P. Herbeuval. 2007. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc. Natl. Acad. Sci. USA 104: 17453-17458. (Pubitemid 350219859)
26. Shimamura, H., R. Cumberland, K. Hiroishi, S. C. Watkins, M. T. Lotze, and J. Baar. 2002. Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. J. Immunother. 25: 226-234. (Pubitemid 34533312)
27. Aiello, S., M. Noris, G. Piccinini, S. Tomasoni, F. Casiraghi, S. Bonazzola, M. Mister, M. H. Sayegh, and G. Remuzzi. 2000. Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. J. Immunol. 164: 4649-4658. (Pubitemid 30238064)
28. Larmonier, N., J. Fraszczak, D. Lakomy, B. Bonnotte, and E. Katsanis. 2010. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol. Immunother. 59: 1-11.
29. Fanger, N. A., C. R. Maliszewski, K. Schooley, and T. S. Griffith. 1999. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190: 1155-1164. (Pubitemid 29496508)
30. Schmitz, M., S. Zhao, Y. Deuse, K. Schäkel, R. Wehner, H. Wöhner, K. Hölig, F. Wienforth, A. Kiessling, M. Bornhäuser, et al. 2005. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J. Immunol. 174: 4127-4134. (Pubitemid 40395990)
31. Yu, Y., S. Liu, W. Wang, W. Song, M. Zhang, W. Zhang, Z. Qin, and X. Cao. 2002. Involvement of tumour necrosis factor-alpha-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccharide-stimulated dendritic cells to activated T cells. Immunology 106: 308-315. (Pubitemid 34748124)
32. Chan, C. W., E. Crafton, H. N. Fan, J. Flook, K. Yoshimura, M. Skarica, D. Brockstedt, T. W. Dubensky, M. F. Stins, L. L. Lanier, et al. 2006. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12: 207-213. (Pubitemid 43214747)
33. Lakomy, D., N. Janikashvili, J. Fraszczak, M. Trad, S. Audia, M. Samson, M. Ciudad, J. Vinit, C. Vergely, D. Caillot, et al. 2011. Cytotoxic dendritic cells generated from cancer patients. J. Immunol. 187: 2775-2782.
34. Cantrell, J., C. Larmonier, N. Janikashvili, S. Bustamante, J. Fraszczak, A. Herrell, T. Lundeen, C. J LaCasse, E. Situ, N. Larmonier, and E. Katsanis. 2010. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology 215: 535-544.
35. Bonnotte, B., N. Larmonier, N. Favre, A. Fromentin, M. Moutet, M. Martin, S. Gurbuxani, E. Solary, B. Chauffert, and F. Martin. 2001. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J. Immunol. 167: 5077-5083. (Pubitemid 33009741)
36. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344. (Pubitemid 39255944)
37. Larmonier, N., C. Billerey, C. Rébé, A. Parcellier, M. Moutet, A. Fromentin, G. Kroemer, C. Garrido, E. Solary, F. Martin, and B. Bonnotte. 2002. An atypical caspase-independent death pathway for an immunogenic cancer cell line. Oncogene 21: 6091-6100.
38. Janikashvili, N., C. J. LaCasse, C. Larmonier, M. Trad, A. Herrell, S. Bustamante, B. Bonnotte, M. Har-Noy, N. Larmonier, and E. Katsanis. 2011. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood 117: 1555-1564.
39. Wesa, A. K., and W. J. Storkus. 2008. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ. 15: 51-57. (Pubitemid 350286172)
40. Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057. (Pubitemid 351871737)
41. Agnello, D., C. S. Lankford, J. Bream, A. Morinobu, M. Gadina, J. J. O'Shea, and D. M. Frucht. 2003. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J. Clin. Immunol. 23: 147-161. (Pubitemid 36522792)
42. Raftery, M. J., M. Schwab, S. M. Eibert, Y. Samstag, H. Walczak, and G. Schönrich. 2001. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15: 997-1009. (Pubitemid 34075379)
43. Vanderheyde, N., E. Aksoy, Z. Amraoui, P. Vandenabeele, M. Goldman, and F. Willems. 2001. Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J. Immunol. 167: 3565-3569. (Pubitemid 32910797)
44. Vanderheyde, N., P. Vandenabeele, M. Goldman, and F. Willems. 2004. Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells. Immunol. Lett. 91: 99-101. (Pubitemid 38296365)
45. Yang, R., D. Xu, A. Zhang, and A. Gruber. 2001. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int. J. Cancer 94: 407-413. (Pubitemid 32906073)
46. Serbina, N. V., T. P. Salazar-Mather, C. A. Biron, W. A. Kuziel, and E. G. Pamer. 2003. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19: 59-70. (Pubitemid 36859901)
47. Chaudhry, U. I., T. P. Kingham, G. Plitas, S. C. Katz, J. R. Raab, and R. P. DeMatteo. 2006. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res. 66: 10497-10504. (Pubitemid 44799771)
48. Ma, D. Y., and E. A. Clark. 2009. The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 21: 265-272.
49. Villadangos, J. A., P. Schnorrer, and N. S. Wilson. 2005. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol. Rev. 207: 191-205. (Pubitemid 41415018)